2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR).
Saved in:
| Title: | 2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). |
|---|---|
| Authors: | Schmidinger, M., Motzer, R.J., Powles, T., Escudier, B., Tannir, N.M., Mainwaring, P.N., Rini, B.I., Hammers, H.J., Donscov, F., Roth, B., Peltola, K., Lee, J.L., Heng, D.Y.C., Aftab, D.T., Hessel, C., Scheffold, C., Schwab, G., Pal, S., Hutson, T.E., Choueiri, T.K. |
| Source: | European Journal of Cancer. Feb2017 Supplement 1, Vol. 72, pS187-S188. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
